The US Food and Drug Administration has approved Zepbound (tirzepatide) as the first prescription medication for the treatment of obstructive sleep apnea (OSA).
The first medication for obstructive sleep apnea has been approved by the US Food and Drug Administration (FDA).
An international committee of experts will release an interim report in early 2025 outlining criteria for diagnosing ...
The United States Food and Drug Administration says the shortage of Eli Lilly’s Zepbound and Mounjaro drugs has been resolved ...
Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 502.93% and ...
The weight loss medication tirzepatide (Mounjaro and Zepbound) is no longer in shortage, according to the FDA. Access to ...
Novo Nordisk has an opportunity to expand indications on its weight loss drugs. Check out on what could be next for NVO stock ...
A new evidence review says that coffee and tea consumption are linked to a lower risk of cancers of the mouth, throat, and head and neck, per the results published in the journal Cancer.
The decision will largely prevent compounding pharmacies from making and selling compounded versions of the drug in the next ...
An international committee of experts will release an interim report in early 2025 outlining criteria for diagnosing ...
Tirzepatide, the active ingredient in both Mounjaro for type 2 diabetes and Zepbound for weight loss, was in short supply for ...
Shares of ResMed and Inspire Medical Systems fell after the FDA approved Eli Lilly's weight-loss drug Zepbound to treat ...